A Clinical Experience with Eperisone Hydrochloride (Myonal®) in Laryngopharyngeal Dysesthesia

Abstract

Phase II of swallowing was radiologically classified in 36 patients with laryngopharyngeal dysesthesia. Eperisone hydrochloride (Myonal®), a muscle relaxant, was administered orally to those patients to determine its effects on the subjective symptoms of laryngopharyngeal dysesthesia. The response was classified as excellent in 4 patients (11%), good in 14 (39%) or fair in 7 (19%). Briefly, an improvement in subjective symptoms of laryngopharyngeal dysesthesia was produced by eperisone hydrochloride in 69% (25/36) of patients. When the results were reviewed in relation to swallowing, the drug produced an improvement in 88% patients (21/24) with epitonic swallowing. It deserves special mention that the drug elicited a higher rate of response in elderly males over 50. Our results seem to justify the conclusion that eperisone hydrochloride is a useful drug for laryngopharyngeal dysesthesia.